Tissue Reaction to Synthetic Oligopeptide Derived from Enamel Matrix Derivative in Rats

Oral Science International

Volumn 7, Issue 1, 2009, Pages 26-36

  Hida, Tomoaki ^a   Tominaga, Kazuya ^a   Tanaka, Akio ^a  

^a OSAKA DENTAL UNIVERSITY   (Japan)

Author keywords

amelogenin; bone formation; enamel matrix; hard tissue; synthetic oligopeptide

Indexed keywords

EID: 84870853754     PISSN: 13488643     EISSN: None     Source Type: Journal    
DOI: 10.11277/osi.osi201001     Document Type: Article

References (23)

1. Ishii T., and Miyamoto Y.: Periodontal regeneration with EMD (enamel matrix derivative). J Jpn Acad Clin Periodontol 25 : 64–69, 2007. (in Japanese).
2. Zetterström O., Andersson C., Eriksson L., Fredriksson A., Friskopp J., Heden G., Jansson B., Lundgren T., Nilveus R., Olsson A., Renvert S., Salonen L., Sjöström L., Winell A., Östgren A., and Gestrelius S.: Clinical safety of enamel matrix derivative (Emdogain®) in the treatment of periodontal defects. J Clin Periodontol 24: 697–704, 1997.
3. Meyle J., Gonzales J.R., Bödeker R.H., Hoffmann T., Richter S., Heinz B., Arjomand M., Reich E., Sculean A., Jepsen K., and Jepsen S.: A randomized clinical trial comparing enamel matrix derivative and membrane treatment of buccal class II furcation involvement in mandibular molars. Part II: secondary outcomes. J Periodontol 75 : 1188–1195, 2004.
4. Yoshie H.: The future of regenerative therapy with enamel matrix derivative. J Jpn Soc Periodontol 43 : 99–106, 2001. (in Japanese).
5. Rasperini G., Silvestri M., and Ricci G.: Long-term clinical observation of treatment of infrabony defects with enamel matrix derivative (Emdogain): surgical reentry. Int J Periodontics Restorative Dent 25 : 121–127, 2005.
6. Esposito M., Grusovin M.G., Coulthard P., and Worthington H.V.: Enamel matrix derivative (Emdogain) for periodontal tissue regeneration in intrabony defects. Cochrane Database Syst Rev 19 : CD003875, 2005.
7. Hammarström L., Heiji L., and Gestrelius S.: Periodontal regeneration in a buccal dehiscence model in monkeys after application of enamel matrix proteins. J Clin Periodontol 24 : 669–677, 1997.
8. Kim N. H., Tominaga K., and Tanaka A.: Analysis of eosinophilic round bodies formed after injection of enamel matrix derivative into the backs of rats. J Periodontol 76 : 1934–1941, 2005.
9. Yuan K., Hsu C. W., and Tsai W. H.: The induction and possible subsequent effect of human antibodies against porcine enamel matrix derivative. J Periodontol 77 : 1355–1361, 2006.
10. Maycock J., Wood S.R., Brookes S.J., Shore R.C., Robinson C., and Kirkham J.: Characterization of a porcine amelogenin preparation, Emdogain, a biological treatment for periodontal disease. Connect Tissue Res 43 : 472–476, 2002.
11. Lerner R.A.: Tapping the immunological repertoire to produce antibodies of predetermined specificity. Nature 299 : 592–596, 1982.
12. Froum S., Weinberg M., Novak J., Mailhot J., Mellonig J., Van Dyke T., McClain P., Papapanou P.N., Childers G., Ciancio S., Blieden T., Polson A., Greenstein G., Yukna R., Wallace M.L., Patters M., and Wagener C.: A multicenter study evaluating the sensitization potential of enamel matrix derivative after treatment of two infrabony defects. J Periodontol 75 : 1001–1008, 2004.
13. Shinnick T.M., Sutcliffe J.G., Green N., and Lerner R.A.: Synthetic peptide immunogens as vaccines. Ann Rev Microbial 37 : 425–446, 1983.
14. Kawanaka A., Tominaga K., and Tanaka A.: Effect of peptide derived from Emdogain® on human periodontal ligament fibroblasts. J Osaka Dent Univ 43 : 111–117, 2009.
15. Hamamoto Y., Hamamoto N., Nakajima T., and Ozawa H.: Morphological changes of epithelial rests of Malassez in rat molars induced by local administration of N-methylnitrosourea. Archs Oral Biol 43 : 899–906, 1998.
16. Sabattini E., Bisgaard K., Ascani S., Poggi S., Piccioli M., Ceccarelli C., Pieri F., Fraternali-Orcioni G., and Pileri S.A.: The EnVisionTM+ system: a new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP, ChemMateTM, CSA, LABC, and SABC techniques. J Clin Pathol 51 : 506–511, 1998.
17. Fincham A.G., Belcourt A.B., Termine J.D., Butler W.T., and Cothran W.C.: Dental enamel matrix: sequences of two amelogenin polypeptides. Bioscience Reports 1 : 771–778, 1981.
18. Fincham A.G., Belcourt A.B., Termine J.D., Butler W.T., and Cothran W.C.: Amelogenins Sequence homologies in enamel-matrix proteins from three mammalian species. Biochem J 211 : 149–154, 1983.
19. Lacerda-Pinheiro S., Jegat N., Septier D., Priam F., Bonnefoix M., Bitard J., Kellermann O., Tompkins K., Veis A., Goldberg M., and Poliard A.: Early in vivo and in vitro effects of amelogenin gene splice products on pulp cell. Eur J Oral Sci 114 : 232–238, 2006.
20. Lyngstadaas S.P., Wohlfahrt J.C., Brookes S.J., Paine M.L., Snead M.L., and Reseland J.E.: Enamel matrix proteins; old molecules for new applications. Orthod Craniofac Res 12 : 243–253, 2009.
21. Johnson W.Jr.: Final report on the safety assessment of PEG-25 propylene glycol stearate, PEG-75 propylene glycol stearate, PRG-120 propylene glycol stearate, PEG-10 propylene glycol, PEG-8 propylene glycol cocoate, and PEG-55 propylene glycol oleate. Int J Toxicol 20 : 13–26, 2001.
22. Shimizu E., Saito R., Nakayama Y., Nakajima Y., Kato N., Takai H., Kim D. S., Arai M., Simmer J., and Ogata Y.: Amelogenin stimulates bone sialoprotein (BSP) expression through fibroblast growth factor 2 response element and transforming growth factor-β1 activation element in the promoter of the BSP gene. J Periodontol 76 : 1482–1489, 2005.
23. D'errico J.A., Ouyang H., Berry J.E., Macneil R.L., Strayhorn C., Imperiale M.J., Harris N.L., Goldberg H., and Somerman M.J.: Immortalized cementoblasts and periodontal ligament cells in culture. Bone 25 : 39–47, 1999.